Skip to main content
. Author manuscript; available in PMC: 2016 Sep 20.
Published in final edited form as: Mol Carcinog. 2015 Aug 21;55(9):1355–1368. doi: 10.1002/mc.22379

Fig. 2. Silencing of SPRY2 upregulates p21 expression and inhibits cell proliferation.

Fig. 2

(A) Caco-2 cells were transiently transfected with non-silencing control (Nsi) or SPRY2 siRNA (50 nM, 72hr). Transfected cells (10,000/well) were then plated in a 96 well plate for 48 hr and cell proliferation was assessed by MTT assay. Data represents means ± SD of three independent experiments, *p< 0.05, compared to Nsi cells (B, C) Caco-2 cells were transiently transfected with non-silencing control (Nsi) or SPRY2 siRNA (50 nM, 72hr). p21 mRNA and protein expression was assessed by RTPCR and western blotting respectively. Data represents means ± SD of three independent experiments, *p< 0.05, compared to Nsi cells (D) Caco-2 cells were transiently transfected with non-silencing control (Nsi) or SPRY2 siRNA (50 nM, 72hr). Cells were serum starved overnight, treated with EGF (10ng/ml) for the indicated times and cell lysates were western blotted for p21 expression. Results represent a representative experiment of three independent experiments. (E) SW480 and SW620 cells were transiently transfected with non-silencing control (Nsi) or SPRY2 siRNA (50 nM, 72hr). p21 protein expression was assessed by western blotting. Data represents means ± SD of three independent experiments, *p< 0.05, compared to Nsi cells.